Three molecular subtypes and a five‐gene signature for hepatocellular carcinoma based on m7G‐related classification DOI

Yuan Yue,

Jie Tao,

Dan An

et al.

The Journal of Gene Medicine, Journal Year: 2023, Volume and Issue: 26(1)

Published: Oct. 17, 2023

Abstract Background The current research investigated the heterogeneity of hepatocellular carcinoma (HCC) based on expression N7‐methylguanosine (m7G)‐related genes as a classification model and developed risk predictive HCC prognosis, key pathological behaviors molecular events HCC. Methods RNA sequencing data were extracted from Cancer Genome Atlas (TCGA)‐live cancer (LIHC) database, carcinoman database (HCCDB) Gene Expression Omnibus respectively. According to level 29 m7G‐related genes, consensus clustering analysis was conducted. least absolute shrinkage selection operator (LASSO) regression COX algorithm applied create prediction normalized five characteristic weighted by coefficients. Tumor microenvironment (TME) performed using MCP‐Counter, TIMER, CIBERSORT ESTIMATE algorithms. Immune Dysfunction Exclusion assess responses immunotherapy in different clusters groups. In addition, patient sensitivity common chemotherapeutic drugs determined biochemical half‐maximal inhibitory concentration R package pRRophetic. Results Three subtypes defined m7G‐associated each which had its specific survival rate, genomic variation status, TME status response. drug showed that C1 subtype more sensitive number conventional oncolytic (including paclitaxel, imatinib, CGP‐082996, pyrimethamine, salubrinal vinorelbine). five‐gene accurately predicted prognosis revealed degree somatic mutations, immune biological events. Conclusion this study, three heterogeneous model, created for predicting providing potential assessment tool understanding variation, mechanisms during development.

Language: Английский

Biomarkers for immunotherapy of hepatocellular carcinoma DOI
Tim F. Greten, Augusto Villanueva, Firouzeh Korangy

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(11), P. 780 - 798

Published: Sept. 19, 2023

Language: Английский

Citations

99
Hepatocellular carcinoma: signaling pathways and therapeutic advances DOI Creative Commons

Jiaojiao Zheng,

Siying Wang, Lei Xia

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2025, Volume and Issue: 10(1)

Published: Feb. 6, 2025

Abstract Liver cancer represents a major global health concern, with projections indicating that the number of new cases could surpass 1 million annually by 2025. Hepatocellular carcinoma (HCC) constitutes around 90% liver and is primarily linked to factors incluidng aflatoxin, hepatitis B (HBV) C (HCV), metabolic disorders. There are no obvious symptoms in early stage HCC, which often leads delays diagnosis. Therefore, HCC patients usually present tumors advanced incurable stages. Several signaling pathways dis-regulated cause uncontrolled cell propagation, metastasis, recurrence HCC. Beyond frequently altered therapeutically targeted receptor tyrosine kinase (RTK) involved differentiation, telomere regulation, epigenetic modification stress response also provide therapeutic potential. Investigating key their inhibitors pivotal for achieving advancements management At present, primary approaches (TKI), immune checkpoint (ICI), combination regimens. New trials investigating therapies involving ICIs TKIs or anti-VEGF (endothelial growth factor) therapies, as well combinations two immunotherapy The outcomes these expected revolutionize across all Here, we here comprehensive review cellular pathways, potential, evidence derived from late-stage clinical discuss concepts underlying earlier trials, biomarker identification, development more effective therapeutics

Language: Английский

Citations

7
Epidemiology, pathophysiology and clinical aspects of Hepatocellular Carcinoma in MAFLD patients DOI
Maria Eva Argenziano, Mi Na Kim, Michele Montori

et al.

Hepatology International, Journal Year: 2024, Volume and Issue: 18(S2), P. 922 - 940

Published: July 16, 2024

Language: Английский

Citations

8
Role of Gut Microbial Metabolites in the Pathogenesis of Primary Liver Cancers DOI Open Access

Maria Pallozzi,

Valeria De Gaetano,

Natalia Di Tommaso

et al.

Nutrients, Journal Year: 2024, Volume and Issue: 16(14), P. 2372 - 2372

Published: July 22, 2024

Hepatobiliary malignancies, which include hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), are the sixth most common cancers third leading cause of cancer-related death worldwide. Hepatic carcinogenesis is highly stimulated by chronic inflammation, defined as fibrosis deposition, an aberrant imbalance between liver necrosis nodular regeneration. In this context, gut-liver axis gut microbiota have demonstrated a critical role in pathogenesis HCC, dysbiosis altered intestinal permeability promote bacterial translocation, to inflammation tumorigenesis through several pathways. A few data exist on or bacteria resident biliary tract CCA, some microbial metabolites, such choline bile acids, seem show association. review, we analyze impact its metabolites HCC CCA development biomarker hepatobiliary cancer risk response during anti-tumor therapy. We also discuss future application management.

Language: Английский

Citations

7
Advances in Histological and Molecular Classification of Hepatocellular Carcinoma DOI Creative Commons
Joon Hyuk Choi, Swan N. Thung

Biomedicines, Journal Year: 2023, Volume and Issue: 11(9), P. 2582 - 2582

Published: Sept. 20, 2023

Hepatocellular carcinoma (HCC) is a primary liver cancer characterized by hepatocellular differentiation. HCC molecularly heterogeneous with wide spectrum of histopathology. The prognosis patients generally poor, especially in those advanced stages. remains diagnostic challenge for pathologists because its morphological and phenotypic diversity. However, recent advances have enhanced our understanding the molecular genetics histological subtypes HCC. Accurate diagnosis important patient management prognosis. This review provides an update on pathology, focusing genetics, subtypes, approaches.

Language: Английский

Citations

15
Efficacy of immunotherapy in hepatocellular carcinoma: Does liver disease etiology have a role? DOI Creative Commons
Elisa Pinto,

Paola Meneghel,

Fabio Farinati

et al.

Digestive and Liver Disease, Journal Year: 2023, Volume and Issue: 56(4), P. 579 - 588

Published: Sept. 25, 2023

The systemic treatment of hepatocellular carcinoma (HCC) is changing rapidly. After a decade tyrosine kinase inhibitors (TKIs), as the only therapeutic option for advanced HCC, in last few years several phase III trials demonstrated efficacy immune checkpoint (ICIs). combination anti-PD-L1 atezolizumab and anti-vascular endothelial growth factor (VEGF) bevacizumab superiority over sorafenib currently represents standard care HCC. In addition, durvalumab (an anti-PD-L1) tremelimumab anti-CTLA4) proved to be superior sorafenib, same trial monotherapy showed non-inferiority compared sorafenib. However, early reports suggest an influence HCC etiology modulating response these drugs. particular, lower effectiveness ICIs has been suggested patients with non-viral (in particular non-alcoholic fatty liver disease). Nevertheless, randomized controlled available date have not stratified data suggesting possible impact outcome managed derive from subgroup pre-specified analyses. this review, we aim examine potential on immunotherapy regimens

Language: Английский

Citations

14
Identification and validation of immune-related gene signature models for predicting prognosis and immunotherapy response in hepatocellular carcinoma DOI Creative Commons
Zhiqiang Liu, Lingge Yang, Chun Liu

et al.

Frontiers in Immunology, Journal Year: 2024, Volume and Issue: 15

Published: June 12, 2024

This study seeks to enhance the accuracy and efficiency of clinical diagnosis therapeutic decision-making in hepatocellular carcinoma (HCC), as well optimize assessment immunotherapy response.

Language: Английский

Citations

5
Perspective on the Role of Gut Microbiome in the Treatment of Hepatocellular Carcinoma with Immune Checkpoint Inhibitors DOI Creative Commons
Ludovico Abenavoli, Michele Montori, Gianluca Svegliati‐Baroni

et al.

Medicina, Journal Year: 2023, Volume and Issue: 59(8), P. 1427 - 1427

Published: Aug. 6, 2023

Background and Objectives: Hepatocellular carcinoma (HCC) is the leading cause of liver cancer worldwide has a high mortality rate. Its incidence increased due to metabolic-associated disease (MAFLD) epidemics. Liver transplantation surgery remain most resolute measures. Despite optimistic use multi-kinase inhibitors, namely sorafenib, co-existence chronic made response rate low in these patients. Immune checkpoint inhibitors (ICIs) have become promising hope for certain advanced solid tumors and, also, HCC. Unfortunately, large cohort patients with HCC fail respond immunotherapy. Materials Methods: We conducted narrative search on main medical databases original articles, reviews, meta-analyses, randomized clinical trials, case series using following keywords acronyms their associations: hepatocellular carcinoma, immunotherapy, gut microbiota, fecal microbiota transplantation. Results: ICIs are sufficiently safe treatment option In detail, they significantly improved survival prognosis vs. sorafenib. Although there several highlighted mechanisms resistance, signature can be used both as biomarker an effect enhancer. Practically, probiotic dose-finding weapons that increase ICI’s treatment-response-reducing resistance mechanisms. Conclusion: Immunotherapy been significant step-up treatment, modulation effective liaison its efficacy.

Language: Английский

Citations

13
Prediction of early treatment response to the combination therapy of TACE plus lenvatinib and anti-PD-1 antibody immunotherapy for unresectable hepatocellular carcinoma: Multicenter retrospective study DOI Creative Commons

Shuqun Li,

Junyi Wu, Jiayi Wu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Feb. 17, 2023

Background and aim The purpose of this study was to investigate validate the efficacy a nomogram model in predicting early objective response rate (ORR) u-HCC patients receiving combination TACE, Lenvatinib, anti-PD-1 antibody treatment after 3 months (triple therapy). Method This included 169 cases from five different hospitals. As training cohorts (n = 102), two major centers were used, external validation 67) drawn other three centers. clinical data contrast-enhanced MRI characteristics retrospective study. For evaluating responses, modified revaluation criteria solid tumors (mRECIST) used. Univariate multivariate logistic regression analyses used select relevant variables develop model. Our as-constructed highly consistent clinically useful, as confirmed by calibration curve decision analysis (DCA); an independent cohort also calibrated nomogram. Results ORR 60.9% risk independently predicted AFP, portal vein tumor thrombus (PVTT), number, size both (C-index 0.853) test 0.800) cohorts. revealed that nomogram-predicted values with actual rates Furthermore, DCA indicated our developed performed well settings. Conclusion accurately predicts achieved triple therapy patients, which aids individual decision-making modifying additional therapies for cases.

Language: Английский

Citations

8
Biomarkers predicting the efficacy of immune checkpoint inhibitors in hepatocellular carcinoma DOI Creative Commons

Ran Qin,

Tianqiang Jin, Feng Xu

et al.

Frontiers in Immunology, Journal Year: 2023, Volume and Issue: 14

Published: Dec. 22, 2023

In recent years, immune checkpoint inhibitors (ICIs) have emerged as a transformative approach in treating advanced hepatocellular carcinoma (HCC). Despite their success, challenges persist, including concerns about effectiveness, treatment costs, frequent occurrence of treatment-related adverse events, and tumor hyperprogression. Therefore, it is imperative to identify indicators capable predicting the efficacy ICIs treatment, enabling optimal patient selection maximize clinical benefits while minimizing unnecessary toxic side effects economic losses. This review paper categorizes prognostic biomarkers into following categories: biochemical cytological indicators, tumor-related markers, imaging personal features, etiology, gut microbiome, immune-related events (irAEs). By organizing these systematically, we aim guide biomarker exploration inform decisions.

Language: Английский

Citations

8